Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358049 | 1.00 | APP (0.63) | APPALOX5AKR1B10AKR1B1TTR | |
| SCHEMBL18608171 | 0.92 | APP (0.65) | APPALOX5AKR1B10AKR1B1TTR | |
| SCHEMBL1269501 | 0.89 | TTR (0.63) | ALOX5TTRDPP4MAOAMAOB | |
| SCHEMBL1269502 | 0.89 | TTR (0.63) | ALOX5TTRDPP4MAOAMAOB | |
| SCHEMBL19637918 | 0.84 | APP (0.62) | APPALOX5AKR1B10AKR1B1TTR | |
| SCHEMBL19244191 | 0.83 | APP (0.60) | APPALOX5MAOAMAOB | |
| SCHEMBL20269219 | 0.83 | APP (0.60) | APPALOX5AKR1B10AKR1B1TTR | |
| SCHEMBL19244190 | 0.83 | APP (0.60) | APPALOX5MAOAMAOB | |
| SCHEMBL19244306 | 0.83 | APP (0.60) | APPALOX5AKR1B10AKR1B1CA12 | |
| SCHEMBL20269220 | 0.83 | APP (0.60) | APPALOX5AKR1B10AKR1B1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723998-B2 | Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells | NORTHEAST NORMAL UNIVERSITY (CN) | 2020-07-28 | — | — | US | claimed |
| US-20180195039-A1 | APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS | NORTHEAST NORMAL UNIVERSITY (CN) | 2018-07-12 | — | — | US | claimed |
| US-10723998-B2 | Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells | NORTHEAST NORMAL UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| US-20180195039-A1 | APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS | NORTHEAST NORMAL UNIVERSITY (CN) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195039-A1 | APPLICATION OF ETHYL P-METHOXYCINNAMATE AND DERIVATIVES THEREOF IN MAINTAINING SELF-RENEWAL AND PLURIPOTENCY OF STEM CELLS | XPA, MEP1A, EED | APP 901/4885ALOX5 3956/4885AKR1B10 4011/4885 |
| US-10723998-B2 | Application of ethyl p-methoxycinnamate and derivatives thereof in maintaining self-renewal and pluripotency of stem cells | XPA, MEP1A, EED | APP 901/4885ALOX5 3956/4885AKR1B10 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.